MA36330B1 - Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease - Google Patents

Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease

Info

Publication number
MA36330B1
MA36330B1 MA36330A MA36330A MA36330B1 MA 36330 B1 MA36330 B1 MA 36330B1 MA 36330 A MA36330 A MA 36330A MA 36330 A MA36330 A MA 36330A MA 36330 B1 MA36330 B1 MA 36330B1
Authority
MA
Morocco
Prior art keywords
kit
diagnosis
monitoring
treatment
residual disease
Prior art date
Application number
MA36330A
Other languages
French (fr)
Other versions
MA20150144A1 (en
Inventor
Moumen Abdeladim
Hassane Sefrioui El
Elamrani Manale
Elhadi Hichem
Bouchoutrouch Nadia
Original Assignee
Mascir Morrocan Foundation For Advanced Science Innovation & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mascir Morrocan Foundation For Advanced Science Innovation & Res filed Critical Mascir Morrocan Foundation For Advanced Science Innovation & Res
Priority to MA36330A priority Critical patent/MA36330B1/en
Priority to PCT/MA2014/000031 priority patent/WO2015060703A2/en
Publication of MA20150144A1 publication Critical patent/MA20150144A1/en
Publication of MA36330B1 publication Critical patent/MA36330B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un kit de diagnostic in vitro pour l'identification et la quantification de la translocation génétique bcr-abl présent dans le cas de leucémie myéloïde chronique (lmc) et la leucémie iymphoblastique aigue (lla). Le présent kit est composée d'une combinaison innovante de nouveaux sets d'amorces et de sondes et d'une série de dilution plasmidique calibrant permettant la détection spécifique et la quantification du gène bcr-abl et du gène de référence abll en utilisant la méthode de pcr en temps réel (qpcr) en format multiplex ou simplex. Le présent kit est destiné pour le diagnostic, le suivi du traitement et l'établissement de la maladie résiduelle dans le cas de la lmcet lla.The present invention relates to an in vitro diagnostic kit for the identification and quantification of the bcr-abl genetic translocation present in the case of chronic myeloid leukemia (lmc) and acute lymphoblastic leukemia (lla). This kit consists of an innovative combination of new primers and probes sets and a calibrated plasmid dilution series for the specific detection and quantification of the abll bcr-abl gene and reference gene using the method real-time pcr (qpcr) in multiplex or simplex format. This kit is intended for the diagnosis, monitoring of treatment and establishment of residual disease in the case of lmcet lla.

MA36330A 2013-10-10 2013-10-10 Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease MA36330B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MA36330A MA36330B1 (en) 2013-10-10 2013-10-10 Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease
PCT/MA2014/000031 WO2015060703A2 (en) 2013-10-10 2014-11-11 Kit for diagnosing chronic myeloid leukaemia in a multiplex reaction and applications of same to monitor the treatment and the residual disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA36330A MA36330B1 (en) 2013-10-10 2013-10-10 Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease

Publications (2)

Publication Number Publication Date
MA20150144A1 MA20150144A1 (en) 2015-05-29
MA36330B1 true MA36330B1 (en) 2016-04-29

Family

ID=52444609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36330A MA36330B1 (en) 2013-10-10 2013-10-10 Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease

Country Status (2)

Country Link
MA (1) MA36330B1 (en)
WO (1) WO2015060703A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106701957A (en) * 2017-01-12 2017-05-24 广州蓝吉生物技术有限公司 Kit for detecting fusion gene BCR-ABL (P210) mRNA expression
CN109706147A (en) * 2018-05-09 2019-05-03 深圳市第二人民医院 Circular RNA circBA9.3 and its use in the preparation of CML diagnostic kits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454994A1 (en) * 2003-03-07 2004-09-08 Université de la Méditerranée Standardized and optimized real-time quantitative reverse transcriptase polymerase chain reaction method for detection of MRD in leukemia
KR100652247B1 (en) * 2004-06-29 2006-12-08 가톨릭대학교 산학협력단 BRC-ALB Quantitative Kit
CN101624621B (en) * 2008-07-11 2012-01-18 北京大学人民医院 Kit for quantitatively detecting BCR/ABL mRNA level
CN101701253B (en) * 2009-11-26 2012-05-30 南方医科大学 A dual fluorescent quantitative PCR kit for detecting gene expression
WO2013036867A2 (en) * 2011-09-08 2013-03-14 The Regents Of The University Of California Compositions and methods for cancer and cancer stem cell detection and elimination
CN102827937B (en) * 2012-09-06 2014-03-19 上海源奇生物医药科技有限公司 Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe
MA35216B1 (en) * 2012-09-13 2014-07-03 Mascir Probes and primers for detecting bcr-abl gene in duplex reaction

Also Published As

Publication number Publication date
WO2015060703A3 (en) 2015-08-13
MA20150144A1 (en) 2015-05-29
WO2015060703A4 (en) 2015-10-01
WO2015060703A2 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
Papantonis et al. TNFα signals through specialized factories where responsive coding and miRNA genes are transcribed
Lahra et al. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia
ES2716104T3 (en) miRNA-124 as a biomarker
Wu et al. Single cell microRNA analysis using microfluidic flow cytometry
Zhang et al. Identification and characterization of miR-92a and its targets modulating Vibrio splendidus challenged Apostichopus japonicus
Ning et al. Characterization of the Merkel cell carcinoma miRNome
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
Mazzoccoli et al. Analysis of clock gene-miRNA correlation networks reveals candidate drivers in colorectal cancer
MA36330B1 (en) Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease
MA37437A1 (en) Breast cancer diagnostic supplies in a multiple qpcr reaction and its application in the assessment of her2 protein status and treatment choice
Tian et al. Expression difference of miR-10b and miR-135b between the fertile and infertile semen samples (p)
CA2978368A1 (en) Signature of health
Batinica et al. Correlation of Merkel cell polyomavirus positivity with PDGFRα mutations and survivin expression in Merkel cell carcinoma
Branford Monitoring after successful therapy for chronic myeloid leukemia
MA35294B1 (en) Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment
ES2674053T3 (en) Diagnosis of hereditary spastic paraplegia (HPS) through the identification of a mutation in the gene or protein ZFYVE26
MA35216B1 (en) Probes and primers for detecting bcr-abl gene in duplex reaction
GB2569932A (en) Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
EA201792628A3 (en) METHOD OF SPECIFIC IDENTIFICATION OF DNA SEQUENCE SPECIFICATIONS
WO2019135477A3 (en) Method of diagnosing tsutsugamushi disease by using multicopy gene
Shires et al. Novel multiplex RT-PCR assay to detect BCR/ABL mRNA variants
KR102602134B1 (en) Method of providing information for diagnosing metastasis of cervical cancer
van Kooten Niekerk et al. Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR‐ABL 1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission
Grätz et al. Extracellular vesicle-associated transcriptomic and proteomic biomarkers show in vitro potential for vandetanib treatment monitoring in anaplastic thyroid cancer
Ewalt et al. Next-Generation Sequencing for Detection of Clonal TRG Gene Rearrangements Shows Improved Specificity and Positive Predictive Value Compared to Fragment Analysis Using BIOMED-2 Primers and Capillary Electrophoresis